Clinical trial · Observational
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Multicentre pilot study (n=90) which aims to study a prevalent population of elderly or frail patients with mCRPC whom are often excluded from clinical trial participation. (Data is sorely needed in this population) 2. The study aims to determine: 1. if symptom monitoring (daily) is feasible using telephone or electronic means of communications in the elderly or frail patient with mCRPC 2. The time course/pattern of symptoms important to quality of life for patients undergoing chemotherapy, abi/enza, or Radium 223 3. If changes in physical activity (quantified by fitbit) predict for changes to ESAS in men undergoing treatment d) Qualitatively assess the supportive care needs of older/frail men with mCRPC
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Daily and weekly triggered symptom monitoring | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Chemotherapy
- description
- 30 participants starting chemotherapy
- interventionNames
- Other: Daily and weekly triggered symptom monitoring
- label
- Abiraterone
- description
- 20 participants starting Abiraterone
- interventionNames
- Other: Daily and weekly triggered symptom monitoring
- label
- Enzalutamide
- description
- 20 participants starting Enzalutamide
- interventionNames
- Other: Daily and weekly triggered symptom monitoring
- label
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. Starting either chemotherapy, Radium-223, Abiraterone or Enzalutamide or starting chemo \> one year post CHAARTED 2. At least 65 years old 3. Able to provide written informed consent 4. Diagnosed with metastatic castrate resistant prostate cancer 5. Total Testosterone level 1.7nmol/L 6. Has a working smartphone OR is willing to use a study provided smartphone Exclusion Criteria: \-
References
Publications (0)
Data not yet available